VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy-A Message from COMET, a French Unicancer Multicentric Study.
SNP
VEGF
bevacizumab
breast cancer
overall survival
pharmacogenetics
precision medicine
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
23 Nov 2020
23 Nov 2020
Historique:
received:
20
10
2020
revised:
17
11
2020
accepted:
18
11
2020
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
27
11
2020
Statut:
epublish
Résumé
The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This study was intended to identify and validate reliable biomarkers to better predict bevacizumab treatment outcomes and allow for a more personalized use of this antiangiogenic agent. To that end, we aimed to establish risk scores for survival prognosis dichotomization based on classic clinico-pathological criteria combined or not with single nucleotide polymorphisms (SNPs). The genomic DNA of 306 patients was extracted and a panel of 13 SNPs, covering seven genes previously documented to be potentially involved in drug response, were analyzed by means of high-throughput genotyping. In receiver operating characteristic (ROC) analyses, the hazard model based on a triple-negative cancer phenotype variable, combined with specific SNPs in
Identifiants
pubmed: 33238394
pii: ph13110414
doi: 10.3390/ph13110414
pmc: PMC7700430
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncotarget. 2017 Nov 06;8(62):105472-105478
pubmed: 29285265
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11701-E11710
pubmed: 30463956
J Oncol Pharm Pract. 2010 Mar;16(1):39-44
pubmed: 19401306
Gut. 2021 Jan;70(1):204-214
pubmed: 32747413
Cancer Treat Rev. 2020 Jun;86:102017
pubmed: 32335505
Expert Rev Clin Pharmacol. 2016 Aug;9(8):1091-108
pubmed: 27031164
J Clin Oncol. 2008 Oct 1;26(28):4672-8
pubmed: 18824714
Int J Mol Sci. 2019 Nov 18;20(22):
pubmed: 31752122
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Heredity (Edinb). 2012 Mar;108(3):285-91
pubmed: 21878986
Future Oncol. 2020 Mar;16(7):225-246
pubmed: 31746224
Br J Clin Pharmacol. 2011 Jun;71(6):921-8
pubmed: 21204912
Nat Rev Immunol. 2011 Sep 23;11(10):702-11
pubmed: 21941296
Annu Rev Med. 2015;66:65-81
pubmed: 25386932
Pharmacogenomics. 2009 Sep;10(9):1489-510
pubmed: 19761371
Curr Protoc Hum Genet. 2009 Jan;Chapter 2:Unit 2.12
pubmed: 19170031